Peter Rehse joins BioFocus as Senior Director, Structural Biology
News Feb 11, 2013
His responsibilities will include managing the structural biology and fragment-based screening groups within the Biological Sciences division.
Peter joins BioFocus from the Chinese CRO Shanghai Medicilon Inc., where, as Vice President, he was responsible for the strategic business and scientific development of the structural biology and structure-based drug design unit. Prior to this Peter worked at RIKEN Harima Institute, in Japan and has held several academic positions in Japan and Canada. Peter studied for his PhD under the supervision of Professor Tom Blundell at the University of London and undertook post-doctoral research at the Max-Planck Institute.
“With Peter’s international credibility we will be able to strengthen and grow our structural biology and fragment screening operation,” commented Dr. Kate Hilyard, VP Biological Sciences, BioFocus. “This hire reflects our ongoing commitment to accelerate our client’s discovery programs through investing in the right people."
Scientists Develop a Synthetic Solution to Combat Dwindling Supply of Cancer and HIV DrugNews
Supplies of a promising drug for cancer, HIV and possibly other diseases is dwindling, and scientists have struggled to extract more from the marine creatures who produce it. Now, chemists have a synthetic solution.READ MORE
Neutrons Observe Vitamin B6-dependent Enzyme Activity Useful for Drug DevelopmentNews
Scientists performed neutron structural analysis of a vitamin B6-dependent protein, potentially opening avenues for new antibiotics and drugs to battle diseases such as drug-resistant tuberculosis, malaria and diabetes.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018